|

BET Bromodomain Inhibitor ZEN-3694 Clinical Trials

8 actively recruiting trials across 6 locations

▲ +1 trial since July 2026

Also known as: BETi ZEN-3694, ZEN 3694, ZEN-3694, ZEN003694

Pipeline

Phase 1: 5Phase 2: 1Phase 1/2: 2

Top Sponsors

  • National Cancer Institute (NCI)8

Indications

  • Cancer8
  • Unresectable Malignant Solid Neoplasm4
  • Metastatic Malignant Solid Neoplasm4
  • Advanced Malignant Solid Neoplasm3
  • Breast Cancer3

Los Angeles, California2 trials

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

Los Angeles General Medical Center

Phase 1/2
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Keck Medicine of USC Koreatown

Phase 1

Boston, Massachusetts2 trials

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

Boston Medical Center

Phase 1
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

Boston Medical Center

Phase 1

Duarte, California1 trial

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

City of Hope Comprehensive Cancer Center

Phase 2

Irvine, California1 trial

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

Phase 1

New Haven, Connecticut1 trial

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

Yale University

Phase 1/2

Augusta, Georgia1 trial

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Augusta University Medical Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.